Education8 min read

GLP-1 Nail Detachment: Study Numbers, Practical Next Steps, and Care Costs

GLP-1 nail detachment headlines need context. See what the survey found, what to ask your clinician, and how to compare support and total costs on PeptidePub.

Short answer: what the headline means

GLP-1 nail detachment was reported more often by medication users in a multinational survey, but the study does not establish that the drugs caused it. If you notice lifting nails, document the change and discuss it with your prescriber while comparing treatment support and total costs on PeptidePub.

Nail detachment, also called onycholysis, describes a nail lifting away from its bed. The useful question is what explains your change, not whether a headline names your medication. Our GLP-1 side-effect management guide provides broader context for that conversation.

The study numbers

The findings were presented at EADV Congress 2026 in Vienna, September 30 to October 3, with a press release dated October 1. Researchers compared 575 GLP-1 users with 1,329 never-users with obesity and/or type 2 diabetes across France, the United States, Brazil and Mexico. That is 1,904 participants in total.

Reported prevalence, users versus never-users:

  • Nail detachment: 39% versus 9%, a 30-percentage-point gap.
  • Any nail disorder: 66% versus 53%, a 13-point gap.
  • Discoloration: 46% versus 17%, a 29-point gap.

These are rounded survey percentages, not the rate of new problems caused by treatment.

Why association is not proof of damage

The detachment headline describes crude prevalence more than four times as high in users. It does not describe an adjusted causal effect. Likewise, the 30-percentage-point gap is not a 30% increase. Neither calculation tells an individual their chance of developing a new problem.

This was a cross-sectional, self-reported questionnaire study, not a randomized trial or prospective nail examination. About half of users already reported nail problems before treatment. That makes timing central to interpretation.

The EADV release says detachment and discoloration remained about two to three times more frequent after adjustment for factors including dermatological conditions and nutritional deficiencies. It does not supply precise adjusted estimates or confidence intervals.

A separate timing analysis matters just as much. In Healthline, author Charles Taieb said the detachment link nearly disappeared when analysis was restricted to changes beginning after treatment started. Adjustment of overall prevalence and restriction to new-onset changes answer different questions. Those results should not be collapsed into a single risk claim.

What the evidence cannot tell you

Weight-loss subgroup differences do not establish a direct drug mechanism. Healthline reported that the available abstract did not specify individual GLP-1 drugs. There is no supported nail-risk ranking of semaglutide versus tirzepatide here, and no basis for extending the findings to every peptide.

The primary release lists institutional support from DUCRAY Laboratories, Pierre Fabre Group. These were conference findings, not automatically a peer-reviewed journal paper. Healthline reported submissions under review in October; current publication status was not independently verified for this November 16 guide.

Build a useful symptom timeline

Take photos and record whether lifting began before or after treatment. Note affected fingers or toes, injury or manicure exposure, weight changes, diet, other medicines, and skin or scalp symptoms.

Bring that record to your prescribing clinician. It helps distinguish injury, infection, inflammatory disease and nutritional issues rather than assigning every change to medication. Ask what findings would change the assessment and how to arrange follow-up. A clear timeline is more useful than a shopping list of products advertised to strengthen nails.

Follow-up and realistic expectations

The authors advise awareness rather than alarm: discuss changes with a doctor instead of independently stopping effective treatment. Painful, red, swollen or draining nails warrant prompt assessment for possible infection. A survey cannot determine whether you need an antifungal, a supplement or a medication change.

Healthline quotes dermatologist Tanya Evans giving approximate replacement-growth times of 4 to 6 months for a fingernail and 9 to 12 months for a toenail. These are general estimates, not a promise of recovery for participants in this study or for your particular nail change.

A companion survey used the same participants, so it is not independent replication. EADV reported unusual hair loss in 50% of users versus 34% of never-users, and volume or density loss in 42% versus 19%. The reported figures for hair loss beginning after treatment initiation were 26% versus 12%.

Our GLP-1 hair-loss and GHK-Cu discussion covers that separate question. Neither survey establishes GHK-Cu, biotin, a peptide stack or a nail product as treatment for onycholysis. Keep the evidence for a symptom separate from evidence for a proposed remedy.

Compare support and the full price

If you are choosing a program, make follow-up access part of the comparison. Ask who reviews a new symptom, how to contact them, and whether that review carries an additional charge. An advertised support channel is not necessarily an appointment with the clinician you need.

Use our semaglutide guide, tirzepatide guide and compound comparison for treatment context, not a nail-risk ranking. Then check current prices, documented vendor information and eligible deals.

Seller testing and chemical purity answer different questions from clinical symptom assessment. Neither proves that a product will prevent nail changes, and changing vendors is not an established solution to onycholysis.

Before committing, request a written total covering the starting period, renewals, medication, membership, shipping and any dose-related price changes. Check which services are included and which depend on eligibility or additional payment. Comparing that written offer with the advertised headline makes the purchase more informed without losing sight of the treatment benefits you are seeking.

A concrete example: $99 is not the treatment total

Checked November 16, 2026, MEDVi's GLP-1 page listed Wegovy pill, Wegovy injection and Zepbound injection at $99 membership plus medication cost. The retrieved text did not expose the medication total or an unambiguous membership billing interval. Treating $99 as the all-in treatment price would therefore be incorrect.

Compounded injection and tablet price fields rendered unresolved placeholders, not usable quotes. Historical review figures of $179 or $249 should not be recycled as current offers. No checkout was tested, and there is no verified discount code supplied here.

MEDVi advertises ongoing support and dietitian/coaching access. Its dietitian footnote makes eligibility and copays conditional. Those are marketing claims and terms to clarify, not evidence of dermatologist access, better outcomes or special nail care.

After applying the full-price and support checklist above, read our MEDVi review for context or inspect the offer through the MEDVi affiliate link. PeptidePub may earn a commission from qualifying purchases through that link. It is a route to review the offer, not an endorsement of nail treatment or a guarantee of the final price.

FAQ: GLP-1 nail detachment

Does this prove Ozempic causes nails to detach? No. The evidence is a self-reported, cross-sectional association with substantial pre-existing symptoms. The available abstract did not break results down by individual drug, so it cannot establish an Ozempic-specific effect or identify a lower-risk alternative.

Does 39% mean my chance of new nail detachment is 39%? No. That is prevalence in the surveyed GLP-1 group, including problems that may have started before medication. It is not treatment-emergent incidence or a personal prediction.

Should I stop or switch medications? Bring photos and the timeline to your prescribing clinician rather than independently stopping effective treatment because of a headline. The cause of your nail change and the benefits of your current treatment belong in the same conversation.

Can GHK-Cu or biotin fix it? These surveys did not test either as treatment. They do not establish a supplement, peptide or stack that reverses detachment. Identifying the cause is the practical next step before deciding whether any targeted treatment makes sense.

What should I compare before signing up?

A named clinician, follow-up access, the symptom-review process and a written full price. Include renewals, medication, membership and conditional services. Check prices and current deals, then confirm the actual terms before checkout.

Bottom line: keep benefits in view and buy informed

This study raises a question worth discussing, not a verdict that effective treatment has failed. Its strongest practical lesson is to separate existing nail problems from new changes and bring that distinction to a clinician who can assess the cause.

Keep the buying decision equally concrete. Choose a plan with clear follow-up, verify what advertised support includes, and compare the full cost rather than a membership-only headline. A transparent offer tells you what is included today and what can change at renewal.

The evidence and price checks in this guide are dated November 16, 2026. They do not establish a drug-specific nail-risk ranking, a preventive product or a guaranteed current checkout total.

Use PeptidePub prices and eligible deals before committing, with vendor documentation alongside them. You can take a symptom seriously while preserving the benefits of treatment and choosing a better-documented, fairly priced program.

Follow @PeptidePub on X for daily peptide price drops.

Get peptide price-drop alerts

Set a target price and we'll email you when a trusted, third-party-tested vendor drops below it. No spam, unsubscribe anytime.

Guides for the peptides in this post

SemaglutideFDA-approved drug
TirzepatideFDA-approved drug

STOP PIECING IT TOGETHER

One article at a time is a slow way to learn peptides.

We wrote the shortcut: five books, 55 compounds, every claim graded by the strength of the real evidence. No hype, no gatekeeping, and free updates for life whenever the market shifts. Most readers say it replaces months of forum digging.

Get the Handbook30-day money-back guarantee. Free updates for life.